Study of BAY1834942 in Patients With Solid Tumors

Phase 1 Completed 30 enrolled Bayer

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody BAY1834942 in patients with advanced solid tumors known to have a prevalence for CEACAM6 expression. The study consists of dose escalation and a tumor type-specific expansion.

Timeline

Start: 2018-06-19
Primary completion: 2020-11-16
Completion: 2021-02-22

Publications

Siu LL, Hong DS, Docke WD, Tetzner R, Trautwein M, Phelps C, Willuda J, Yu XQ, Nogai H, Johnson M, Goh BC. A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. Target Oncol. 2025 Jul;20(4):637-649. doi: 10.1007/s11523-025-01154-4. Epub 2025 Jun 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BAY1834942	Unknown	2.5 mg	Intravenous
Subject	BAY1834942	Unknown	30 mg	Intravenous
Subject	BAY1834942	Unknown	100 mg	Intravenous

Indications

No indication recorded.